Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study currently not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-03